-
Pitavastatin (NK-104): Protocols for Cholesterol Inhibition
2026-07-30
Pitavastatin (NK-104) is a validated HMG-CoA reductase inhibitor optimized for in vitro and biochemical studies targeting cholesterol biosynthesis, especially in cardiovascular and atherosclerosis research models. It is not recommended for clinical or in vivo animal use without further validation, and strict adherence to lab protocols is essential for reproducible results.
-
Expanding EGF’s Translational Impact: Mechanism to Strategy
2026-07-30
This thought-leadership article explores the multifaceted potential of Epidermal Growth Factor (EGF), human recombinant, as a linchpin in translational research. Integrating cutting-edge mechanistic insights, recent chemogenetic screening findings, and competitive benchmarks, we provide actionable guidance for scientists seeking to harness EGF’s unique properties in cell proliferation, mucosal healing, and cancer modeling. The discussion highlights APExBIO's high-purity recombinant human EGF, framed by rigorous evidence and workflow-relevant recommendations.
-
Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Mechan
2026-07-29
This article analyzes a recent open-access study demonstrating that intravesical delivery of p21 mRNA–loaded lipid nanoparticles (LNPs) restores tumor suppressor function and suppresses tumor growth in non–muscle-invasive bladder cancer. The work establishes a clinically compatible, localized mRNA-based approach, with implications for the future of targeted cancer therapy.
-
Neuromedin S (rat): Technical Use in GPCR Signaling Workflow
2026-07-29
Neuromedin S (rat) provides a chemically defined agonist for controlled activation of neuromedin U receptor signaling in rat-based GPCR/G protein research. It addresses the need for reproducible peptide reagents in energy homeostasis and stress response studies, but is not intended for diagnostic, therapeutic, or in vivo applications.
-
NDRG2–DRP1 Axis Drives Mitochondrial Fission in Pulmonary Hy
2026-07-28
This study identifies NDRG2 as a pivotal regulator of DRP1-mediated mitochondrial fission in pulmonary arterial smooth muscle cells (PASMCs), directly linking it to vascular remodeling and the progression of pulmonary hypertension. The findings clarify a mechanistic pathway and highlight the therapeutic potential of targeting NDRG2–DRP1 interactions in PH.
-
Native Protein Electrophoresis Redefined: Unpacking the Basi
2026-07-28
Explore the scientific foundations and innovative applications of the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0). This in-depth analysis reveals how native protein gel electrophoresis advances functional proteomics and experimental accuracy.
-
Microsphere Modulation Enhances TIL Therapy in Solid Tumors
2026-07-27
Li et al. introduce alginate-based microspheres co-loaded with hyaluronidase and CXCL9 to remodel the tumor microenvironment, significantly improving the yield and function of tumor-infiltrating lymphocytes (TILs) for cell therapy. This approach accelerates ex vivo TIL expansion and enhances antitumor efficacy, presenting a promising strategy to overcome barriers in solid tumor immunotherapy.
-
Prestained Protein Marker (Triple color, EDTA free, 10-250 k
2026-07-27
The Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa) provides visible, multi-color molecular weight standards for SDS-PAGE and Western blot workflows, streamlining protein size verification and transfer QC without interfering with phosphoprotein or fluorescent analyses. It is not suitable for direct protein quantitation or workflows requiring unstained or EDTA-containing markers.
-
LGK-974 (PORCN Inhibitor): Precision Targeting of Wnt-Driven
2026-07-26
Explore the scientific rigor and translational impact of LGK-974, a potent PORCN inhibitor for Wnt signaling pathway modulation. This article uniquely dissects assay design, tumor model selection, and mechanistic integration, equipping researchers to advance Wnt-driven cancer therapy.
-
Anti Reverse Cap Analog: Advancing mRNA Translation Efficien
2026-07-25
Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G, empowers researchers to maximize protein expression from synthetic mRNA through orientation-specific capping. This reagent is pivotal for mRNA therapeutics, cell reprogramming, and high-throughput protein production, with proven results in stem cell and gene editing workflows.
-
PFOS Induces Ferroptosis and ER Stress in HK-2 Kidney Cells
2026-07-24
This study elucidates how perfluorooctane sulfonate (PFOS) induces injury in human kidney HK-2 cells via ferroptosis and endoplasmic reticulum (ER) stress pathways. By characterizing key molecular changes and cell death mechanisms, the findings provide a mechanistic foundation for toxicology research and highlight potential intervention targets in PFOS-induced nephrotoxicity.
-
Synergistic Antibacterial Action of Copper and Hexetidine In
2026-07-24
This study demonstrates that combining copper and hexetidine produces a strong synergistic antibacterial effect against Streptococcus sobrinus and Streptococcus sanguis. These findings inform rational design of multi-agent antibacterial protocols and highlight the mechanistic importance of cell surface modulation for enhanced metal ion uptake.
-
Acute and Chronic Toxicity of Sulfamonomethoxine in Aquatic
2026-07-23
This study provides quantitative evidence on the acute and chronic toxicity of the sulfonamide antibiotic sulfamonomethoxine (SMM) across multiple aquatic organisms. By systematically characterizing species-specific sensitivities, the research informs both environmental risk assessment and the design of reproducible aquatic toxicity assays.
-
WY-14643 (Pirinixic Acid): Targeting Pyroptosis in Liver Inj
2026-07-23
Discover how WY-14643 (Pirinixic Acid), a selective PPARα agonist, offers a novel approach for mitigating cholestatic liver injury by inhibiting pyroptosis. This article delivers expert insight into the mechanistic and translational implications for metabolic and inflammation research.
-
Omeprazole (A2845): Protocols for Gastric Acid Secretion Res
2026-07-22
Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor formulated for research on gastric acid secretion and antiulcer mechanisms, supporting robust modeling of peptic ulcer disease and related disorders. This product should not be used for diagnostic or clinical purposes, and is strictly intended for controlled laboratory workflows.